Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury.
Open Access
- 1 July 1993
- journal article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 90 (13) , 6189-6193
- https://doi.org/10.1073/pnas.90.13.6189
Abstract
Carvedilol is a cardiovascular drug currently used for the treatment of hypertension. Clinical studies have recently demonstrated efficacy in angina and congestive heart failure. Recently, carvedilol has been shown to attenuate oxygen free radical-initiated lipid peroxidation and to inhibit vascular smooth muscle mitogenesis induced by a wide variety of growth factors. These findings are of interest since smooth muscle proliferation and abnormal lipid metabolism are proposed to play an important role in the pathogenesis of atherosclerotic plaque formation and in development of stenotic lesions following vascular injury by balloon angioplasty and coronary artery bypass grafting. On the basis of these observations, the antiproliferative actions of carvedilol have been explored in detail. In human cultured pulmonary artery vascular smooth muscle cells, carvedilol (0.1-10 microM) produced a concentration-dependent inhibition of the mitogenesis stimulated by platelet-derived growth factor, epidermal growth factor, thrombin, and serum, with IC50 values ranging from 0.3 to 2.0 microM. Carvedilol also produced a concentration-dependent inhibition of vascular smooth muscle cell migration induced by platelet-derived growth factor, with an IC50 value of 3 microM. The extensive neointimal formation that occurs following balloon angioplasty of rat carotid arteries was markedly attenuated by carvedilol (1 mg/kg, i.p.; twice daily starting 3 days before angioplasty and continuing until 14 days after angioplasty). Quantitative image analysis demonstrated that carvedilol reduced the neointimal growth following angioplasty by 84% without altering either medial or adventitial cross-sectional areas. These observations indicate that carvedilol may also be effective in the treatment of pathological disorders principally associated with abnormal vascular smooth muscle growth, such as atherosclerosis and acute vascular wall injury induced by angioplasty or coronary artery bypass grafting.Keywords
This publication has 23 references indexed in Scilit:
- Carvedilol Inhibits Vascular Smooth Muscle Cell ProliferationJournal of Cardiovascular Pharmacology, 1993
- Carvedilol, a new antihypertensive, prevents oxidation of human low density lipoprotein by macrophages and copperAtherosclerosis, 1992
- Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivoNature, 1992
- Inhibition of cultured vascular smooth muscle cell migration by simvastatin (MK-733)Atherosclerosis, 1992
- Silent myocardial ischemia after coronary angioplasty: Distinguishing the shadow from the substanceJournal of the American College of Cardiology, 1992
- Inhibition of converting enzyme and neointima formation after vascular injury in rabbits and guinea pigs.Hypertension, 1991
- Effect of Ramipril, an Inhibitor of Angiotensin Converting Enzyme, on the Response of Rat Thoracic Aorta to Injury with a Balloon CatheterJournal of Cardiovascular Pharmacology, 1991
- Suppression of the vascular response to injury: The role of angiotensin-converting enzyme inhibitorsJournal of the American College of Cardiology, 1991
- Inhibitory effect of calcium antagonists on balloon catheter-induced arterial smooth muscle cell proliferation and lesion sizeAtherosclerosis, 1988
- The Pathogenesis of Atherosclerosis — An UpdateNew England Journal of Medicine, 1986